HealthQuest Capital, a Menlo Park, CA-based investor in emerging companies in healthcare innovation, closed its latest fund, at $225m.
Investors in HealthQuest Capital II, LP, include endowments, family offices, foundations, fund-of-funds, pension funds, and global healthcare organizations.
The fund will focus on commercial stage companies that are optimizing value to the healthcare system and improving the efficiency of healthcare delivery, providing capital towards growing revenues and scaling businesses.
Investments will concentrate in areas of medical products, diagnostics, healthcare IT, and technology-enabled healthcare services.
Led by Randy Scott, David Kabakoff, Ph.D., Richard Lin, M.D., Tom Callaway, M.D., and Marie Casey, Ph.D., HealthQuest Capital has invested in BioTheranostics (cancer molecular diagnostics), Castle Biosciences (rare cancer diagnostics), First Aid Shot Therapy (consumer medicine), InMediata (automated payment solutions), Lineagen (developmental delay diagnostics), Spirox Medical (minimally invasive device for nasal obstruction), Trice (optical needle for in-office diagnostic arthroscopy), Vestagen (advanced textiles for healthcare), and VirMedica (improving patient access to specialty products).